Is epinephrine (adrenaline) considered an inotrope?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Epinephrine an Inotrope?

Yes, epinephrine is definitively classified as an inotrope with potent positive inotropic effects mediated through beta-adrenergic receptor stimulation that increases myocardial contractility and cardiac output. 1, 2

Mechanism of Inotropic Action

Epinephrine exerts its inotropic effects through direct myocardial stimulation that increases the strength of ventricular contraction (positive inotropic action), alongside increased heart rate (positive chronotropic action). 2 The drug acts on both alpha and beta-adrenergic receptors, with the beta-1 receptor stimulation specifically responsible for enhanced cardiac contractility. 3, 4

At low doses (<0.3 mcg/kg/min), epinephrine predominantly produces β-adrenergic effects including increased inotropy and decreased systemic vascular resistance, while at higher doses (>0.3 mcg/kg/min), α-adrenergic vasoconstriction effects become more prominent. 1

Clinical Classification and Dosing

Epinephrine is formally classified as an "inoconstrictор"—a medication that provides both inotropic support and vasopressor effects. 4 This distinguishes it from pure inotropes like dobutamine (inodilators) and pure vasopressors like phenylephrine. 4

The European Society of Cardiology recommends epinephrine as an inotropic agent with a recommended infusion rate of 0.05-0.5 μg/kg/min in acute heart failure management. 1 Guidelines explicitly list epinephrine alongside other recognized inotropes with specific dosing recommendations for its inotropic effects. 3, 1

Context-Specific Use

When Epinephrine IS Recommended as an Inotrope:

  • Neonatal hypoxic-ischemic encephalopathy with shock: The American Academy of Pediatrics recommends epinephrine as the first-line inotrope (0.05-0.3 μg/kg/min) due to potent inotropic effects and superior outcomes compared to dopamine in this population. 5
  • Cardiac arrest resuscitation: Standard dosing of 2-10 mcg/min for advanced cardiac life support. 3
  • Septic shock (dose-dependent): Produces linear increases in cardiac index, stroke volume, and oxygen delivery in the 3-18 microgram/min range without affecting systemic vascular resistance or pulmonary artery occlusion pressure. 6

When Epinephrine Should Be AVOIDED Despite Inotropic Properties:

  • Cardiogenic shock: The European Society of Cardiology explicitly states that epinephrine is NOT recommended as an inotrope or vasopressor in cardiogenic shock and should be restricted to rescue therapy in cardiac arrest only. 7 This is a critical caveat—while epinephrine IS an inotrope pharmacologically, it should not be used for this indication in cardiogenic shock due to increased myocardial oxygen demand and arrhythmia risk. 3, 7

Important Clinical Caveats

All inotropes, including epinephrine, increase myocardial oxygen demand, ischemic burden, and risk of malignant arrhythmias, necessitating use at the lowest possible doses for the shortest duration. 3 The standard dosage for advanced cardiac life support is 2-10 mcg/min with titration to hemodynamic response, though higher doses may result in vasoconstriction or arrhythmias. 3

Epinephrine displays dose-proportional pharmacokinetics with rapid onset (<5 minutes) and short duration of action (offset within 20 minutes), achieving steady state within 10-15 minutes of continuous infusion. 2 This rapid clearance (effective half-life <5 minutes) requires continuous infusion for sustained inotropic effect. 2

References

Guideline

Inotropic Effects of Epinephrine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit.

Journal of cardiovascular pharmacology and therapeutics, 2015

Guideline

Inotrope Selection for Neonates with Hypoxic-Ischemic Encephalopathy and Shock

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Cardiogenic Shock

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.